Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose tamoxifen for breast cancer risk reduction in post-menopausal women
NCT07806630Phase 2Active, not recruiting
- Sponsor
- Rutgers University
- Start
- Sep 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen in breast cancer, sponsored by Rutgers University. Started Sep 2026; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07806630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806630.